Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.
- Q1 revenue reaches $1.2 million
- 76% of PTSD patients show significant improvement
- New clinics opening in Victoria and NSW
- Global Partnership Program launched for drug sponsors
- Clinic utilisation improving in Perth and Brisbane
Revenue Growth and Clinical Outcomes Highlight Quarter
Emyria Limited (ASX:EMD) recorded $1.2 million in revenue during the March quarter, a notable increase driven primarily by insurer-funded mental health clinics. The company’s PTSD treatment program demonstrated durable clinical outcomes, with 76% of patients achieving clinically significant improvement and 67% remaining in remission 12 months post-treatment. These results underscore Emyria’s emerging role in delivering effective psychedelic-assisted therapies.
Clinic utilisation rates in Perth and Brisbane have been steadily rising, reflecting growing patient demand and operational efficiency. The Empax clinic network continues to expand, with the first Victorian clinic on track for a Q2 FY26 opening, and a new clinic partnership secured with Matilda Nepean Private Hospital in New South Wales, boosting treatment capacity ahead of a planned launch later this year. This expansion aligns with Emyria’s strategy to grow its footprint nationally and capitalise on rising mental health treatment needs. The company’s recent Empax Clinics to New South Wales partnership announcement provides further detail on this development.
Global Partnership Program Targets International Drug Sponsors
Emyria launched its Global Partnership Program during the quarter, aiming to leverage its clinical infrastructure to support international drug sponsors developing psychedelic-assisted therapies. This initiative positions Emyria as a key clinical delivery partner in a sector experiencing rapid global research and regulatory momentum. The US government’s recent executive order to accelerate psychedelic drug research and patient access adds to the favourable environment for such partnerships.
With a dual-revenue model combining clinical services and drug development support, Emyria is capitalising on scarce clinical delivery capacity worldwide. The program is already operational with North American sponsor Psyence Biomed, reflecting early traction and validating the company’s strategic approach. This builds on the company’s Global Partnership Program launch reported previously.
Regulatory and Operational Developments
Emyria continues to navigate regulatory complexities inherent to psychedelic-assisted therapies. The Therapeutic Goods Administration (TGA) currently restricts funded treatments to fourth-line therapy with stringent criteria, while the Department of Veterans’ Affairs (DVA) engagement clarifies pre-treatment pathways. The company is actively advocating to broaden eligible disciplines for therapy delivery and has established dedicated teams to streamline authorised prescriber applications.
Authorised prescriber numbers vary by location, with eight approved in Perth, three in Brisbane, and one in Melbourne, alongside several psychiatrists in the application pipeline. These efforts aim to expand patient access and clinic utilisation, which is already increasing at the Empax clinics.
Future Catalysts and Market Positioning
Looking ahead, Emyria plans to expand its indications beyond PTSD to capture larger addressable markets and grow clinic capacity through new site partnerships. Optimising clinic utilisation and adding new drug partners to funded programs remain key priorities. The company’s capital-light model, combined with durable clinical outcomes and first-mover advantage in psychedelic-assisted therapies, underpins its growth strategy.
Emyria’s leadership team blends clinical services expertise with global innovation and health IT experience, supporting the company’s ambitions in a rapidly evolving sector. The company’s March quarter presentation highlighted these strategic pillars and operational progress, setting the stage for upcoming milestones.
Bottom Line?
Emyria’s expanding clinic network and strong PTSD outcomes position it well for growth, but regulatory hurdles and the unproven safety profile of some compounds warrant close attention.
Questions in the middle?
- How will regulatory changes in Australia and internationally impact Emyria’s therapy rollout timelines?
- Can Emyria sustain revenue growth while scaling clinic utilisation across new states?
- What clinical data on MDMA-inspired compounds will emerge to influence market acceptance?